vs
Side-by-side financial comparison of AC Immune SA (ACIU) and Draganfly Inc. (DPRO). Click either name above to swap in a different company.
Draganfly Inc. is the larger business by last-quarter revenue ($1.7M vs $1.4M, roughly 1.2× AC Immune SA). Draganfly Inc. runs the higher net margin — -409.2% vs -1622.4%, a 1213.2% gap on every dollar of revenue. On growth, AC Immune SA posted the faster year-over-year revenue change (90.1% vs -8.7%).
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.
Draganfly Inc. is a technology firm specializing in commercial drone design, manufacturing, and sales, plus supporting software and custom aerial data solutions. It serves public safety, agriculture, industrial inspection, disaster response, and mapping segments, with core North American markets and a global client base.
ACIU vs DPRO — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $1.7M |
| Net Profit | $-23.3M | $-7.1M |
| Gross Margin | — | 26.6% |
| Operating Margin | -1484.5% | — |
| Net Margin | -1622.4% | -409.2% |
| Revenue YoY | 90.1% | -8.7% |
| Net Profit YoY | 6.9% | -2.6% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $1.4M | — | ||
| Q2 24 | $755.7K | $1.7M | ||
| Q2 23 | — | $1.9M | ||
| Q3 22 | $4.3M | — |
| Q2 25 | $-23.3M | — | ||
| Q2 24 | $-25.0M | $-7.1M | ||
| Q2 23 | — | $-6.9M | ||
| Q3 22 | $-14.9M | — |
| Q2 25 | — | — | ||
| Q2 24 | — | 26.6% | ||
| Q2 23 | — | 24.6% | ||
| Q3 22 | — | — |
| Q2 25 | -1484.5% | — | ||
| Q2 24 | -3051.1% | — | ||
| Q2 23 | — | — | ||
| Q3 22 | -342.2% | — |
| Q2 25 | -1622.4% | — | ||
| Q2 24 | -3313.0% | -409.2% | ||
| Q2 23 | — | -363.8% | ||
| Q3 22 | -343.6% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $28.3M | $5.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $82.2M | $-2.6M |
| Total Assets | $209.2M | $9.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $28.3M | — | ||
| Q2 24 | $56.7M | $5.3M | ||
| Q2 23 | — | $6.7M | ||
| Q3 22 | $49.0M | — |
| Q2 25 | $82.2M | — | ||
| Q2 24 | $135.8M | $-2.6M | ||
| Q2 23 | — | $8.7M | ||
| Q3 22 | $209.1M | — |
| Q2 25 | $209.2M | — | ||
| Q2 24 | $261.3M | $9.9M | ||
| Q2 23 | — | — | ||
| Q3 22 | $226.1M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
